Amgen is investing $1 billion to establish a second drug substance manufacturing facility in North Carolina. This brings the company’s total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
 
The $1 billion facility will incorporate cutting-edge technologies. In tandem with the existing facility, these investments will create 370 new jobs in the region.
 
“This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact.”